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Discussion
Dr J. Cox (Washington, DC). Dr Raman and his colleagues at
the other 19 hospitals in this multicenter study are to be com-
mended for achieving these rather striking results, especially the
100% cure rate of AF at 12 and 18 months. When I first read these
results several weeks ago, I had difficulty believing them. How-
ever, on closer inspection, I think it is clear that the explanation for
these remarkable results resides in the design criteria of the mul-
ticenter study.
As Dr Raman pointed out, the 2 principles to which all the
participants adhered in this study were that the pattern of lesions
would correspond as closely as possible to those of either the maze
or radial procedures, both of which are proved procedures, and that
every effort would be made to be certain that every portion of
every lesion was transmural.
By adhering to these 2 fundamental principles, the results could
have been predicted, I think, because every previous study that has
taken this approach has resulted in essentially the same results.
This strongly implies, though, that as long as the lesion pattern is
correct and the lesions are transmural, the particular method for
creating those lesions is immaterial to the outcome. In other words,
any energy source or technique that is capable of creating the
correct lesion pattern and is uniformly transmural will result in a
cure of AF in essentially all patients.
I have 2 questions for Dr Raman. Why do you think the results
improved with time, because that has not been the experience in
most other studies? Second, you note that there was no AF on
long-term follow-up, but did those patients ever experience epi-
sodes of atrial flutter?
I congratulate Dr Raman and his associates on a well-designed
and important study.
Dr Raman. Thank you very much, Dr Cox. It is a privilege to
actually have you discuss this paper because you served as an
inspiration for us to actually set up this protocol. I will answer the
second question first. In terms of flutter, we had one patient who
had one episode of flutter late, and it resolved spontaneously. This
was asymptomatic flutter, and fortunately, the patient was actually
reviewed at that time by his cardiologist and local doctor. On
subsequent Holter monitoring, he was found to be in sinus rhythm,
and therefore he did not actually need further medications or
specific intervention. A few years ago this man ran marathons. He
was in his 70s, and he went back to running up hills. He said he
used to experience tachycardia or felt palpitations coming on when
he ran up a hill, but he did not have this experience postopera-
tively, and I think this was a chance finding that he actually had
flutter, which was relatively slow.
The first question concerns the improvement in AF over time.
I think almost definitely that this procedure does nothing to reduce
the propensity toward early postoperative AF. We all know that
postoperative AF in patients undergoing any cardiac surgical pro-
cedure is about 30%, and despite all the different manipulations,
such as magnesium infusions and -blockade, this still seems a
bugbear. We did not see a difference. Early in the experience, we
were very enthusiastic, and some of the surgeons applied these
procedures in all kinds of patients. I think they have actually been
a lot more selective later on. As our experience grew, we have also
been more aggressive in using cardioversion early on, which might
account for the improvement in the recovery of sinus rhythm. The
other interesting thing, and this is an observation that we have
seen, is that patients who have been followed up for 3 months who
seem to be in fibrillation and then at the 6-month mark they have
reverted to sinus rhythm. I know that this is anecdotal, but I have
at least 3 patients with that, and other people have had similar
experiences. I cannot explain it, but I think they seem to stabilize
electrically with the passage of time.
Dr Joao Melo (Lisbon, Portugal). Congratulations on a beau-
tiful paper. I am happy to see those results, which are much better
than most reported results, including ours. But to understand
whether we are comparing the same type of patients, I noticed that
25% of your patients were not in chronic AF. Therefore, it is
important to know how many of your patients with mitral valve
disease were part of this group of patients. My first question is to
know whether this a selected population. My second question
regards the issue of pacemakers because it is also very striking that
you did your lines on the Cox maze concept and you are reporting
no need for postoperative pacemakers. Can you elaborate on the
reason for that finding?
Dr Raman. As I said, this is a reporting of what we have seen
with this probe, and I cannot speak for specific indications in other
centers, but all patients that had documented AF and came up
initially for mitral valve surgery and later on for coronary artery
surgery or early valve replacement surgery were enrolled, and as
they got more familiar with the technique, they started getting
more confident with it. I cannot tell you with the AF how many of
them had mitral valve disease, but we will look at that carefully.
Dr Ralph Damiano (St Louis, Mo). I would like to echo both
Dr Cox’s and Dr Melo’s congratulations on a beautiful study. One
of the objectives of the maze procedure, or any type of surgery for
AF, is to allow patients to discontinue antiarrhythmic drugs, which
have a high incidence of side effects. I noticed you did not mention
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that, but I was wondering what percentage of your patients were
both in sinus rhythm and free of antiarrhythmic drugs and what
percentage were also free of chronic anticoagulation?
Dr Raman. I knew someone would ask that. As I said, this,
again, is a work in evolution. When we first started off, we did not
use any antiarrhythmics as a routine, but there were suggestions
from others, particularly electrophysiologists, that using low-dose
amiodarone perioperatively might help. What we have recom-
mended, and not all the surgeons adhere to this because amioda-
rone does provoke strong feelings among surgeons, is that we put
patients on 200 mg/d amiodarone postoperatively for the first 3
months, but that has not been strictly adhered to. In terms of
long-term data, none of the 15 patients who are out close to 24
months are on any antiarrhythmic medications. In terms of anti-
coagulation, 30% at 3 months were on anticoagulation, 20%of
them were for a mechanical valve, because, as in the United States,
we see some amount of rheumatic disease. It is not as much as
other places, but there is a definite proportion of patients who have
mechanical valves. Out at 6 months it decreases to 20%, but at
the 12-month mark with our first group of patients, 3 of them
had mechanical valves. Therefore, 25% of that first group of
patients that have gone beyond 12 months are on anticoagula-
tion.
Regarding the other question that Dr Melo asked about pace-
makers, we did have 4 pacemakers, so it is not zero, and I think as
we follow these patients up further we might see, as Dr Damiano
presented in his series yesterday, an increasing incidence of pace-
makers for sinus bradycardia.
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